Chardan Capital Lifts Earnings Estimates for Immuneering

Immuneering Co. (NASDAQ:IMRX) – Stock analysts at Chardan Capital upped their FY2025 earnings per share (EPS) estimates for Immuneering in a report released on Tuesday, May 6th. Chardan Capital analyst G. Livshits now expects that the company will post earnings of ($1.36) per share for the year, up from their prior forecast of ($1.65). Chardan Capital currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Immuneering’s current full-year earnings is ($1.86) per share. Chardan Capital also issued estimates for Immuneering’s FY2026 earnings at ($0.54) EPS.

Several other research firms have also weighed in on IMRX. Oppenheimer reduced their price objective on Immuneering from $25.00 to $21.00 and set an “outperform” rating on the stock in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $12.00 target price on shares of Immuneering in a research note on Thursday, April 10th.

Immuneering Stock Performance

IMRX opened at $1.14 on Friday. Immuneering has a 1 year low of $1.00 and a 1 year high of $3.83. The company’s 50 day simple moving average is $1.43 and its 200 day simple moving average is $1.78. The stock has a market capitalization of $41.02 million, a PE ratio of -0.58 and a beta of -0.22.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Marshall Wace LLP purchased a new stake in shares of Immuneering during the fourth quarter worth about $47,000. HighTower Advisors LLC increased its stake in shares of Immuneering by 33.7% in the fourth quarter. HighTower Advisors LLC now owns 71,360 shares of the company’s stock worth $157,000 after buying an additional 18,000 shares during the last quarter. Rockefeller Capital Management L.P. acquired a new stake in Immuneering in the fourth quarter valued at $390,000. XTX Topco Ltd grew its holdings in Immuneering by 177.2% during the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock worth $72,000 after acquiring an additional 20,871 shares in the last quarter. Finally, Two Sigma Investments LP increased its position in shares of Immuneering by 25.0% in the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock worth $111,000 after purchasing an additional 10,126 shares during the last quarter. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.